X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ALEMBIC PHARMA - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ALEMBIC PHARMA BIOCON /
ALEMBIC PHARMA
 
P/E (TTM) x 18.3 15.9 115.1% View Chart
P/BV x 2.9 3.5 83.3% View Chart
Dividend Yield % 0.4 1.1 36.4%  

Financials

 BIOCON    ALEMBIC PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
ALEMBIC PHARMA
Mar-19
BIOCON /
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188664 178.9%   
Low Rs305412 74.0%   
Sales per share (Unadj.) Rs68.7208.7 32.9%  
Earnings per share (Unadj.) Rs7.631.0 24.4%  
Cash flow per share (Unadj.) Rs14.037.1 37.6%  
Dividends per share (Unadj.) Rs1.005.50 18.2%  
Dividend yield (eoy) %0.11.0 13.1%  
Book value per share (Unadj.) Rs86.3144.2 59.9%  
Shares outstanding (eoy) m600.00188.52 318.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.6 421.2%   
Avg P/E ratio x98.917.4 569.3%  
P/CF ratio (eoy) x53.414.5 368.5%  
Price / Book Value ratio x8.63.7 231.7%  
Dividend payout %13.217.7 74.6%   
Avg Mkt Cap Rs m447,900101,461 441.4%   
No. of employees `0006.1NA-   
Total wages/salary Rs m9,3117,467 124.7%   
Avg. sales/employee Rs Th6,705.8NM-  
Avg. wages/employee Rs Th1,514.2NM-  
Avg. net profit/employee Rs Th736.9NM-  
INCOME DATA
Net Sales Rs m41,23439,347 104.8%  
Other income Rs m2,06294 2,198.3%   
Total revenues Rs m43,29639,441 109.8%   
Gross profit Rs m8,2918,736 94.9%  
Depreciation Rs m3,8511,152 334.2%   
Interest Rs m615184 334.1%   
Profit before tax Rs m5,8877,493 78.6%   
Minority Interest Rs m21311 1,972.2%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5691,568 100.1%   
Profit after tax Rs m4,5315,844 77.5%  
Gross profit margin %20.122.2 90.6%  
Effective tax rate %26.720.9 127.4%   
Net profit margin %11.014.9 74.0%  
BALANCE SHEET DATA
Current assets Rs m41,48619,577 211.9%   
Current liabilities Rs m21,41314,896 143.7%   
Net working cap to sales %48.711.9 409.2%  
Current ratio x1.91.3 147.4%  
Inventory Days Days6490 71.3%  
Debtors Days Days9445 207.7%  
Net fixed assets Rs m50,66127,097 187.0%   
Share capital Rs m3,000377 795.8%   
"Free" reserves Rs m48,80826,811 182.0%   
Net worth Rs m51,80827,188 190.6%   
Long term debt Rs m17,8984,993 358.5%   
Total assets Rs m99,89747,778 209.1%  
Interest coverage x10.641.7 25.4%   
Debt to equity ratio x0.30.2 188.1%  
Sales to assets ratio x0.40.8 50.1%   
Return on assets %5.212.6 40.8%  
Return on equity %8.721.5 40.7%  
Return on capital %9.623.6 40.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05819,453 62.0%   
Fx outflow Rs m7,3486,065 121.2%   
Net fx Rs m4,71013,388 35.2%   
CASH FLOW
From Operations Rs m6,6218,120 81.5%  
From Investments Rs m-6,840-7,556 90.5%  
From Financial Activity Rs m-2,397590 -406.0%  
Net Cashflow Rs m-2,6121,153 -226.5%  

Share Holding

Indian Promoters % 40.4 74.1 54.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 2.9 289.7%  
FIIs % 10.7 9.1 117.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 13.9 143.2%  
Shareholders   109,995 49,328 223.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  UNICHEM LAB  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)

Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jun 14, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS